Tango to launch Phase 3 trial in pancreatic cancer after promising combo results
read at Endpoints ↗Positive readoutPositive
Tango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer.
The decision follows data presented at the American Society of Clinical Oncology meeting, where Revolution Medicines reported strong results with its drug daraxonrasib in combination.
If the Phase 3 study confirms the early findings, it could represent a significant advance for a disease with limited treatment options.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Tango plans Phase 3 pancreatic cancer study after combo success”
read at Endpoints ↗81 words · retrieved Jun 8
comments(0)
5-min edit window · permanent after that